Rational Design and Synthesis of a Metalloproteinase-Activatable Probe for Dual-Modality Imaging of Metastatic Lymph Nodes in Vivo

2019 ◽  
Vol 84 (10) ◽  
pp. 6126-6133 ◽  
Author(s):  
Ling Yin ◽  
Hao Sun ◽  
Meng Zhao ◽  
Anna Wang ◽  
Shanshan Qiu ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Rational Design ◽  
Metastatic Lymph Nodes ◽  
Dual Modality ◽  
Design And Synthesis ◽  
Metastatic Lymph ◽  
Dual Modality Imaging ◽  
Activatable Probe

PS02.078: FEASIBILITY OF PREOPERATIVE STAGING WITH USPIO ENHANCED MRI IN PATIENTS WITH RESECTABLE ESOPHAGEAL CARCINOMA (PRECIES STUDY)

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 142-142
Author(s):  
Didi De Gouw ◽  
Bastiaan Klarenbeek ◽  
Chella Van Der Post ◽  
John Hermans ◽  
Marnix Maas ◽  
...  
Keyword(s):  
Mechanical Ventilation ◽  
Esophageal Cancer ◽  
Lymph Nodes ◽  
Ex Vivo ◽  
Metastatic Lymph Nodes ◽  
Enhanced Mri ◽  
Metastatic Lymph ◽  
Before And After ◽  
Controlled Mechanical Ventilation

Abstract Background In operable patients suffering from esophageal cancer, the percentage of patients without metastatic lymph nodes found after neoadjuvant chemoradiotherapy (nCRT) is 69%. Extensive lymph node dissections during esophagectomy may be omitted or minimized in these patients, reducing associated morbidity. Recently, MRI with ultrasmall superparamagnetic iron oxide nanoparticles (USPIO, ferumoxtran-10) has been reintroduced to detect metastatic lymph nodes in prostate cancer. The aim of this study is to assess the feasibility of USPIO-MRI to detect loco-regional lymph node metastases in patients with esophageal cancer. Methods USPIO-nanoparticles are intravenously infused 24 to 36 hours before MRI. USPIO-enhanced MRI is performed before and after nCRT. After nCRT, patients are scanned under general anesthesia immediately prior to surgery in the MR system of the hybrid MITeC operation room with controlled mechanical ventilation. During controlled prolonged apneu, a four-minute iron-sensitive MRI acquisition is used to visualize suspicious esophageal lymph nodes without motion artefacts. Resected specimens, still containing USPIO, are measured ex-vivo in a preclinical 7T MR system before histopathological examination. A radiological assessment of the presence of suspicious lymph nodes in-vivo is matched to the ex-vivo nodes on preclinical MRI, providing the ground truth for the presence of metastases. Results Currently, three patients were included in the study of which one patient has been examined before and after nCRT. MRI under anesthesia prior to surgery with controlled mechanical ventilation was possible resulting in a clinically relevant spatial resolution to visualize possible malignant lymph nodes. Suspicious nodes were identified and could be matched using corresponding anatomical landmarks to the ex-vivo MRI, which showed good visual agreement with esophageal specimen after resection. Conclusion A successful method was proposed to validate USPIO-enhanced MRI to detect metastatic lymph nodes in patients with esophageal cancer. Matching ex-vivo USPIO-MRI images with histopathology results provides direct information for validation of in vivo USPIO-MRI and characteristics of loco-regional lymph nodes. Final results on the feasibility of USPIO-MRI to detect metastatic lymph nodes after nCRT are still awaited. Feasibility and preliminary values of the accuracy of the technique are the starting point for a phase two study. Disclosure All authors have declared no conflicts of interest.

pH‐amplified CRET nanoparticles for in vivo imaging of tumor metastatic lymph nodes

2021 ◽  
Author(s):  
Zenghui Wang ◽  
Heming Xia ◽  
Binlong Chen ◽  
Yaoqi Wang ◽  
Qingqing yin ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
In Vivo Imaging ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph

pH‐amplified CRET nanoparticles for in vivo imaging of tumor metastatic lymph nodes

2021 ◽  
Author(s):  
Zenghui Wang ◽  
Heming Xia ◽  
Binlong Chen ◽  
Yaoqi Wang ◽  
Qingqing yin ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
In Vivo Imaging ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph

Differentiation of Hyperplastic from Metastatic Lymph Nodes Using a Lymph Node Specific MR Contrast Agent Gadofluorine M

2006 ◽  
Vol 55 (2) ◽  
pp. 183 ◽  
Author(s):  
Joo Hee Cha ◽  
Woo Kyung Moon ◽  
Jung Eun Cheon ◽  
Young Hwan Koh ◽  
Eun Hye Lee ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Nodes ◽  
Contrast Agent ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph ◽  
Gadofluorine M

ENT private eye for unknown primary metastatic lymph nodes

ORL ro ◽  
2019 ◽  
Vol 1 (42) ◽  
pp. 20
Author(s):  
Daniela Vrînceanu ◽  
Mihai Dumitru ◽  
Adriana Nica
Keyword(s):  
Lymph Nodes ◽  
Unknown Primary ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph ◽  
Private Eye

scholarly journals Apparent diffusion coefficient cannot discriminate metastatic and non-metastatic lymph nodes in rectal cancer: a meta-analysis

2021 ◽  
Author(s):  
Alexey Surov ◽  
Hans-Jonas Meyer ◽  
Maciej Pech ◽  
Maciej Powerski ◽  
Jasan Omari ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Diffusion Coefficient ◽  
Apparent Diffusion Coefficient ◽  
Lymph Nodes ◽  
Meta Analysis ◽  
Adc Value ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph ◽  
Apparent Diffusion ◽  
Adc Values

Abstract Background Our aim was to provide data regarding use of diffusion-weighted imaging (DWI) for distinguishing metastatic and non-metastatic lymph nodes (LN) in rectal cancer. Methods MEDLINE library, EMBASE, and SCOPUS database were screened for associations between DWI and metastatic and non-metastatic LN in rectal cancer up to February 2021. Overall, 9 studies were included into the analysis. Number, mean value, and standard deviation of DWI parameters including apparent diffusion coefficient (ADC) values of metastatic and non-metastatic LN were extracted from the literature. The methodological quality of the studies was investigated according to the QUADAS-2 assessment. The meta-analysis was undertaken by using RevMan 5.3 software. DerSimonian, and Laird random-effects models with inverse-variance weights were used to account the heterogeneity between the studies. Mean DWI values including 95% confidence intervals were calculated for metastatic and non-metastatic LN. Results ADC values were reported for 1376 LN, 623 (45.3%) metastatic LN, and 754 (54.7%) non-metastatic LN. The calculated mean ADC value (× 10−3 mm2/s) of metastatic LN was 1.05, 95%CI (0.94, 1.15). The calculated mean ADC value of the non-metastatic LN was 1.17, 95%CI (1.01, 1.33). The calculated sensitivity and specificity were 0.81, 95%CI (0.74, 0.89) and 0.67, 95%CI (0.54, 0.79). Conclusion No reliable ADC threshold can be recommended for distinguishing of metastatic and non-metastatic LN in rectal cancer.

Sign in / Sign up

Export Citation Format

Share Document